Glenmark Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Glenmark Pharmaceuticals's earnings have been declining at an average annual rate of -20.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 7% per year.
Key information
-20.7%
Earnings growth rate
-20.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 7.0% |
| Return on equity | -6.9% |
| Net Margin | -5.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10Increases to Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Might Cool off for now
Sep 17Glenmark Pharmaceuticals' (NSE:GLENMARK) Dividend Will Be ₹2.50
Aug 27Revenue & Expenses BreakdownBeta
How Glenmark Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 131,575 | -7,640 | 35,454 | 0 |
| 30 Sep 23 | 137,510 | -1,263 | 34,998 | 0 |
| 30 Jun 23 | 136,144 | 2,546 | 28,740 | 0 |
| 31 Mar 23 | 129,901 | 2,972 | 33,653 | 0 |
| 31 Dec 22 | 126,355 | 8,811 | 31,713 | 0 |
| 30 Sep 22 | 123,451 | 8,305 | 30,013 | 0 |
| 30 Jun 22 | 121,173 | 8,277 | 24,874 | 0 |
| 31 Mar 22 | 123,049 | 9,417 | 29,176 | 0 |
| 31 Dec 21 | 122,103 | 10,202 | 28,735 | 0 |
| 30 Sep 21 | 118,248 | 10,464 | 28,841 | 0 |
| 30 Jun 21 | 116,144 | 10,226 | 24,305 | 0 |
| 31 Mar 21 | 109,439 | 9,700 | 28,103 | 0 |
| 31 Dec 20 | 107,778 | 9,565 | 29,386 | 0 |
| 30 Sep 20 | 107,445 | 8,992 | 28,992 | 0 |
| 30 Jun 20 | 106,629 | 9,207 | 22,777 | 0 |
| 31 Mar 20 | 106,573 | 7,760 | 28,627 | 0 |
| 31 Dec 19 | 104,370 | 7,173 | 29,403 | 0 |
| 30 Sep 19 | 102,564 | 6,428 | 28,861 | 0 |
| 30 Jun 19 | 100,227 | 7,680 | 20,903 | 0 |
| 31 Mar 19 | 98,655 | 9,250 | 28,738 | 0 |
| 31 Dec 18 | 95,532 | 8,863 | 26,688 | 0 |
| 30 Sep 18 | 92,018 | 8,721 | 26,317 | 0 |
| 30 Jun 18 | 89,057 | 6,716 | 19,400 | 0 |
| 31 Mar 18 | 90,744 | 8,039 | 25,149 | 0 |
| 31 Dec 17 | 91,908 | 6,420 | 25,123 | 0 |
| 30 Sep 17 | 95,055 | 10,083 | 24,474 | 0 |
| 30 Jun 17 | 94,896 | 10,233 | 23,733 | 0 |
| 31 Mar 17 | 90,794 | 9,160 | 23,601 | 0 |
| 31 Dec 16 | 89,316 | 10,402 | 21,486 | 0 |
| 30 Sep 16 | 81,749 | 7,508 | 20,918 | 0 |
| 30 Jun 16 | 78,414 | 7,292 | 20,078 | 0 |
| 31 Mar 16 | 75,732 | 7,021 | 19,219 | 0 |
| 31 Dec 15 | 70,300 | 5,697 | 25,618 | 1,624 |
| 30 Sep 15 | 69,530 | 5,141 | 25,335 | 1,624 |
| 30 Jun 15 | 67,244 | 4,814 | 24,904 | 1,624 |
| 31 Mar 15 | 65,561 | 4,753 | 15,454 | 0 |
| 31 Dec 14 | 64,891 | 5,078 | 21,404 | 1,414 |
| 30 Sep 14 | 63,983 | 6,092 | 20,973 | 1,414 |
| 30 Jun 14 | 61,897 | 5,984 | 20,065 | 1,414 |
| 31 Mar 14 | 59,450 | 5,423 | 19,409 | 1,414 |
| 31 Dec 13 | 56,441 | 6,660 | 9,575 | 0 |
| 30 Sep 13 | 54,241 | 6,627 | 8,964 | 0 |
| 30 Jun 13 | 52,163 | 6,651 | 8,335 | 0 |
Quality Earnings: GLENMARK is currently unprofitable.
Growing Profit Margin: GLENMARK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLENMARK is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.
Accelerating Growth: Unable to compare GLENMARK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLENMARK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: GLENMARK has a negative Return on Equity (-6.93%), as it is currently unprofitable.